Instalab

Minimum FFRCT - RCA Test

Your non-invasive read on whether a narrowing in your right coronary artery is actually starving your heart.

Should you take a Minimum FFRCT - RCA test?

This test is most useful if any of these apply to you.

Dealing With Chest Pain
This test can show whether a narrowing in your right coronary artery is actually limiting blood flow, often without needing a catheterization.
Have a High Calcium Score
If your calcium score is elevated, this test tells you whether the plaque has progressed to the point of choking off blood flow yet.
Living With Diabetes
Silent flow-limiting disease in the coronary arteries is more common in diabetes than people realize, and this test can detect it before symptoms appear.
Strong Family History of Heart Attacks
If a close relative had a heart attack young, this test gives you a direct read on whether the inherited risk has already started to affect your arteries.

About Minimum FFRCT - RCA

You can have a visible narrowing in a coronary artery on a CT scan and still be fine. The question that actually matters is whether that narrowing is choking off blood flow to your heart muscle. The minimum FFRCT (CT-derived fractional flow reserve) value along your right coronary artery (RCA) is the lowest pressure ratio measured along that vessel, and it answers exactly that question without a single catheter.

This is the same physiological information cardiologists used to obtain only by threading a wire into your coronary arteries. Now it can be calculated by software from the images of a standard heart CT scan. When the number drops below 0.80, your right coronary artery is likely flow-limited and your risk of heart attack, death, and the need for a stent climbs sharply.

What This Number Actually Measures

FFRCT is not a substance in your blood. It is a dimensionless ratio between 0 and 1 calculated by computer software that simulates blood flow through your coronary arteries using your CT scan images. A value of 1.0 means flow is unobstructed. The lower the number, the more pressure is being lost as blood pushes past narrowings in the artery.

The minimum FFRCT-RCA is the single lowest value found anywhere along the right coronary artery. The RCA supplies blood to the bottom and back of your heart and, in most people, to the heart's electrical pacemaker. A blockage here can cause heart attacks that disrupt your heart rhythm in dangerous ways, which is part of why measuring its function specifically is useful.

Why the 0.80 Threshold Matters

Across major validation studies, a minimum FFRCT value of 0.80 or below is treated as the line where a narrowing becomes hemodynamically significant. This threshold was borrowed from the invasive wire-based version of the test, where it has decades of outcome data behind it. Above 0.80, the artery is generally not flow-limited. At or below 0.80, the narrowing is starving the downstream heart muscle of blood under stress.

There is a known gray zone between 0.71 and 0.80 where the test agrees less well with invasive measurement. Values in this range warrant individualized judgment rather than automatic referral for an invasive procedure. Values at or below 0.70 carry high specificity for true ischemia and almost always justify further workup.

Heart Attack and Death Risk

A large pooled cohort of 2,566 people with coronary artery disease followed for about six years found that a CT-FFR value at or below 0.80 was associated with roughly five times the risk of major adverse cardiovascular events compared with a value above 0.80, after adjusting for clinical risk factors and the anatomy seen on the CT scan itself. Adding the FFRCT measurement to a model based on clinical risk and anatomy improved the model's predictive performance and reclassified people into more accurate risk categories.

A meta-analysis of five studies covering 5,460 patients with 12-month follow-up showed that people with an abnormal FFRCT (at or below 0.80) had a 2.3 times higher risk of dying from any cause or having a heart attack compared with those above 0.80. The relationship was continuous: each 0.10-unit drop in FFRCT was associated with a 67% higher risk of death or heart attack.

In a three-year follow-up of 900 patients with stable angina from the ADVANCE registry, those with a lesion-specific FFRCT at or below 0.80 had a 6.6% rate of death or non-fatal heart attack compared with 2.1% in those above 0.80, a roughly three-fold higher risk.

Why the Right Coronary Artery Behaves Differently

The RCA has quirks that affect how its FFRCT values should be read. Even in arteries with no significant narrowing, the pressure ratio naturally declines as you move from the start of the vessel toward its end. In one study of RCAs without obstructive disease, the value frequently dipped below 0.80 in the distal portion despite less than 50% narrowing on the scan itself. The strongest predictor of this distal drop was the ratio of the artery's interior volume to its length, with a value of 8.1 cubic millimeters per millimeter being the optimal cutoff for predicting a low distal FFRCT.

In a study of asymptomatic marathon runners with no coronary stenosis, 7% had distal RCA FFRCT values at or below 0.80. This was tied to smaller distal RCA diameters (around 1.4 to 1.5 millimeters). What looks like ischemia in a small distal segment can simply be the physics of pressure loss in a narrow tube, not actual disease.

The practical implication: a low FFRCT in the very distal RCA without a clear narrowing upstream is not the same finding as a low value sitting just past a visible plaque. The location of the minimum matters as much as the number itself.

Reconciling the Distal-Vessel Paradox

It can seem contradictory that a healthy-looking artery on the scan can produce a low FFRCT value. This is not a failure of the test, it is a feature of the underlying physics. FFRCT measures pressure loss along the entire artery, and small distal vessels naturally lose pressure even without disease. The number is most informative when interpreted alongside the anatomy: a low value just downstream of a visible plaque is meaningful, while a low value in a tapering distal segment without upstream disease is often an artifact of vessel size.

Reference Ranges

These thresholds come from validation studies comparing FFRCT against invasive wire-based fractional flow reserve, predominantly in symptomatic adults referred for coronary CT. They are widely used clinically but are not adjusted for age, sex, ethnicity, or vessel-specific differences. Your scan will report a single ratio, and the cutoff your reading cardiologist applies should match these tiers.

TierMinimum FFRCT-RCA ValueWhat It Suggests
NormalAbove 0.80No significant flow limitation in the right coronary artery
Gray Zone0.71 to 0.80Uncertain; agreement with invasive testing is lowest here, decisions should be individualized
Abnormal0.70 or belowHigh likelihood of true flow-limiting disease; further workup typically warranted

Sources: Matsumura-Nakano et al. 2019; ADVANCE registry analyses; NXT trial.

What this means for you: a single value above 0.80 in the RCA is reassuring across multiple large cohorts, with very low event rates over the next one to three years. A value at or below 0.70 is rarely a false alarm in symptomatic people with visible coronary disease. Values in between deserve a careful conversation with a cardiologist who can look at the location of the minimum, the upstream plaque, and your symptoms together.

Tracking Your Trend

FFRCT is not a routine repeat test the way a cholesterol panel is. The CT scan itself involves radiation and contrast dye, so most people will not repeat it every year. But the value of serial measurement comes into play when something has changed: new symptoms, a major intervention like starting a PCSK9 inhibitor (a class of cholesterol-lowering injectable drugs) after a baseline scan, or a question about whether a previously borderline narrowing has progressed.

A reasonable cadence for someone with an abnormal or borderline baseline is repeat coronary CT with FFRCT every two to five years, sooner if symptoms change or if you start an aggressive plaque-modifying therapy and want to confirm anatomic and physiologic improvement. The single most important comparison is within the same imaging center using the same FFRCT vendor, because results across vendors can differ.

What to Do With an Abnormal Result

A minimum FFRCT-RCA at or below 0.80 should trigger a structured workup, not panic. First, look at the location of the minimum. A value sitting just downstream of a visible 50 to 70% narrowing in the proximal or mid RCA is the highest-yield finding. A value in the very distal RCA with no upstream plaque is much more likely to reflect normal pressure decay in a small vessel.

Second, get the other pieces of your coronary picture: a full lipid workup including ApoB (apolipoprotein B, a measure of the number of cholesterol-carrying particles) and Lp(a) (lipoprotein little a, an inherited cholesterol-like particle), an inflammatory marker like hs-CRP (high-sensitivity C-reactive protein, a measure of low-grade body-wide inflammation), and a coronary artery calcium score if not already obtained. Third, see a cardiologist, ideally one who reads coronary CTs themselves, to decide whether invasive angiography is warranted or whether aggressive medical therapy with serial follow-up is the better path. Many people with an abnormal FFRCT are now managed with intensive lipid lowering and lifestyle change without ever undergoing a catheterization.

When Results Can Be Misleading

FFRCT calculations depend on the quality of the underlying CT scan. Several factors can distort the result:

  • Heavy calcification: dense calcium in the artery wall can blur the lumen on CT and degrade the FFRCT calculation, though the test still performs reasonably well even in arteries with very high calcium burden.
  • Image quality issues: motion from a fast or irregular heart rhythm, breath-holding problems during the scan, or low-resolution images can all reduce the accuracy of the simulation.
  • Small distal vessels: values can fall below 0.80 in very thin distal segments of the RCA purely because of vessel size, not disease. Always check whether the low value sits downstream of a real narrowing.
  • Measurement location: the FFRCT value reported just at the very end of the artery can overestimate ischemia. Values measured roughly 10 millimeters downstream of the narrowing itself give a truer picture of lesion-specific flow limitation.

What Moves This Biomarker

Evidence-backed interventions that affect your Minimum FFRCT - RCA level

Increase
High-intensity statin therapy (rosuvastatin or atorvastatin at maximal doses)
High-intensity statins reduce the size of coronary plaques over months to years, which should improve flow through narrowed arteries and raise the FFRCT value. The direct effect on minimum FFRCT-RCA has not been measured. The evidence comes from imaging studies of plaque volume: in the ASTEROID trial of 507 patients (349 with evaluable serial imaging), rosuvastatin 40 mg daily produced regression of coronary atherosclerosis on intravascular ultrasound after 24 months. If your FFRCT is borderline or abnormal, aggressive statin therapy is the foundational treatment to slow or reverse the disease process driving that number.
MedicationModerate Evidence
Increase
PCSK9 inhibitors (evolocumab, alirocumab) added to statin therapy
PCSK9 inhibitors are injectable medications that dramatically lower LDL (low-density lipoprotein) cholesterol and shrink coronary plaques on top of statin therapy, which should translate to improved FFRCT values, though this has not been directly tested. In the GLAGOV trial of 968 statin-treated patients, evolocumab produced significant plaque regression compared with placebo. The PACMAN-AMI trial of 300 people after a heart attack found that adding alirocumab to a high-intensity statin produced greater plaque regression in non-culprit arteries over 52 weeks. For someone with an abnormal FFRCT and stubbornly elevated ApoB despite statins, adding a PCSK9 inhibitor is a logical next step.
MedicationModerate Evidence
Increase
Ezetimibe combined with a statin
Ezetimibe is a daily pill that blocks cholesterol absorption from the gut. Added to a statin, it produces additional plaque regression compared with a statin alone. The PRECISE-IVUS trial of 202 people undergoing percutaneous coronary intervention showed greater plaque regression with atorvastatin plus ezetimibe than with atorvastatin alone. The downstream effect on FFRCT has not been measured, but the mechanistic case for improvement is strong.
MedicationModest Evidence

Frequently Asked Questions

References

33 studies
  1. Nørgaard B, Leipsic J, Gaur S, Seneviratne S, Ko B, Ito H, Jensen J, Mauri L, De Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis a, Park SJ, Christiansen EH, Kaltoft a, Lassen J, Bøtker H, Achenbach SJournal of the American College of Cardiology2014
  2. Cami E, Tagami T, Raff G, Fonte TA, Renard BM, Gallagher MJ, Chinnaiyan K, Bilolikar a, Fan a, Hafeez a, Safian RJournal of Cardiovascular Computed Tomography2018
  3. Fairbairn T, Nieman K, Akasaka T, Nørgaard B, Berman D, Raff G, Hurwitz-koweek L, Pontone G, Kawasaki T, Sand N, Jensen J, Amano T, Poon M, ØVrehus KA, Sonck J, Rabbat M, Mullen S, De Bruyne B, Rogers C, Matsuo H, Bax JJ, Leipsic J, Patel MEuropean Heart Journal2018
  4. Nørgaard B, Gaur S, Fairbairn T, Douglas P, Jensen J, Patel M, Ihdayhid a, Ko B, Sellers S, Weir-mccall J, Matsuo H, Sand N, ØVrehus KA, Rogers C, Mullen S, Nieman K, Parner E, Leipsic J, Abdulla JHeart2021
  5. Rabbat M, Leipsic J, Bax JJ, Kauh B, Verma R, Doukas D, Allen S, Pontone G, Wilber D, Mathew V, Rogers C, Lopez JJJournal of Clinical Medicine2020